Bozbas Huseyin, Yildirir Aylin, Muderrisoglu Haldun
Department of Cardiology, Baskent University Hospital, F. Cakmak Cad. 10.sok, Bahcelievler 06490 Ankara, Turkey.
Clin Med Res. 2006 Mar;4(1):79-84. doi: 10.3121/cmr.4.1.79.
Diagnostic accuracy of the currently available serum markers of cardiac injury, such as myoglobin, creatine kinase and its myocardial isoform, are altered in patients with renal failure. It is shown that cardiac troponins have decreased diagnostic sensitivity and specificity in patients receiving renal replacement therapy. Data regarding serum levels of these cardiac biomarkers, especially those of the cardiac troponins, in patients with a transplanted kidney are limited. Current data show that levels of cardiac troponin I are unaltered in patients who have undergone renal transplantation, while levels of cardiac troponin T may be elevated.We believe that cardiac troponin I should be the biomarker of choice for diagnosis of myocardial injury in these patients. However, further trials are required for conclusive results.
目前可用的心脏损伤血清标志物,如肌红蛋白、肌酸激酶及其心肌同工酶,在肾衰竭患者中的诊断准确性会发生改变。研究表明,心脏肌钙蛋白在接受肾脏替代治疗的患者中诊断敏感性和特异性降低。关于肾移植患者这些心脏生物标志物的血清水平,尤其是心脏肌钙蛋白的血清水平的数据有限。目前的数据表明,肾移植患者的心脏肌钙蛋白I水平未改变,而心脏肌钙蛋白T水平可能升高。我们认为心脏肌钙蛋白I应该是这些患者心肌损伤诊断的首选生物标志物。然而,需要进一步的试验才能得出确凿的结果。